10 active not recruiting. 10 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Active not recruiting 10 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks - Focal Epilepsy | Phase 3 | Active not recruiting | Praxis Precision Medicines | 300 | 2026-01-29 | 2026-08-03 |
| Effect of Different Anesthetic Drugs on Electrocorticography (ECOG). Fentanyl (IV), Ketamine (0.5 mg/kg) - Epilepsy, Brain Tumor | Phase 3 | Active not recruiting | Children's Cancer Hospital Egypt 57357 | 88 | 2025-08-18 | 2025-09-10 |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo - Developmental and Epileptic Encephalopathy 1 | Phase 3 | Active not recruiting | Praxis Precision Medicines | 160 | 2025-07-09 | 2026-08-04 |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome zorevunersen, Sham Comparator - Dravet Syndrome | Phase 3 | Active not recruiting | Stoke Therapeutics, Inc | 170 | 2025-06-04 | 2026-10-20 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) LP352, Placebo - Dravet Syndrome | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 108 | 2024-09-25 | 2026-10-27 |
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Active not recruiting | UCB Biopharma SRL | 70 | 2024-07-10 | 2026-08-27 |
| Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-05-13 | 2026-08-13 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy BHV-7000, Placebo - Focal Epilepsy | Phase 2 / Phase 3 | Active not recruiting | Biohaven Therapeutics Ltd. | 390 | 2024-03-14 | 2026-09-30 |
| A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure | Phase 3 | Active not recruiting | Zogenix, Inc. | 87 | 2022-03-08 | 2026-04-29 |
Seizures (5) · Epilepsies, Partial (3) · Drug Resistant Epilepsy (2) · Epilepsies, Myoclonic (2) · Neurodevelopmental Disorders (2) · Brain Neoplasms (1) · CDKL5 deficiency disorder (1) · Epilepsy, Absence (1) · Epilepsy, Tonic-Clonic (1) · Infantile Epileptic-Dyskinetic Encephalopathy (1) · Lennox Gastaut Syndrome (1) · Spasms, Infantile (1)
Brain Diseases (10) · Central Nervous System Diseases (10) · Nervous System Diseases (10) · Epileptic Syndromes (5) · Neurologic Manifestations (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Epilepsy, Generalized (4) · Mental Disorders (2) · Central Nervous System Neoplasms (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Neoplasms (1) · Neoplasms by Site (1)
Fenfluramine (1) · Fentanyl (1) · Ketamine (1) · brivaracetam (1)
Biohaven Therapeutics Ltd. (2) · Longboard Pharmaceuticals (2) · Praxis Precision Medicines (2) · Children's Cancer Hospital Egypt 57357 (1) · Stoke Therapeutics, Inc (1) · UCB Biopharma SRL (1) · Zogenix, Inc. (1)
United States (9) · Italy (6) · Germany (5) · Spain (5) · United Kingdom (5) · Australia (4) · Belgium (4) · France (4) · Japan (4) · Portugal (4) · Brazil (3) · China (3) · Mexico (3) · Netherlands (3) · Austria (2)
Praxis Precision Medicines (1) · Suzan A. Abdelrahman, consultant (1)
2023 (4)